ALGO Drops 5.72% as E-Commerce and Biotech News Distract Investors

Generated by AI AgentCryptoPulse AlertReviewed byAInvest News Editorial Team
Thursday, Nov 20, 2025 12:19 pm ET1min read
Aime RobotAime Summary

- ALGO dropped 5.72% in 24 hours to $0.1447, reflecting broader market uncertainty and lack of ecosystem catalysts.

- Allegro's e-commerce growth (17.2% YoY) contrasted with 2025 GMV forecast cuts due to weak winter demand.

- Argo Graphene's concrete test showed 11% strength improvement, but no direct link to crypto markets.

- Alvotech's 33% stock plunge followed FDA manufacturing concerns and revised 2025 guidance.

- Analysts attribute ALGO's decline to macroeconomic sentiment, not sector-specific developments.

On NOV 20 2025, the price of

fell 5.72% within 24 hours to $0.1447, reflecting broader market uncertainty. Over the past 7 days, the token lost 12.29%, 19.11% in the last month, and a significant 57.1% over the past year. The decline aligns with a broader lack of immediate catalysts in the ALGO ecosystem, despite activity across related sectors.

Allegro Posts Mixed E-Commerce Results

Poland’s leading e-commerce firm Allegro reported strong domestic third-quarter earnings, rising 17.2% year-over-year to 1.04 billion zlotys, surpassing analyst expectations. The performance was driven by reduced delivery costs, increased advertising revenue, and gains from its consumer lending arm. However, the company also cut its gross merchandise value (GMV) forecast for 2025, citing slower-than-expected demand in the early winter season. While Allegro’s core operations showed resilience, the earnings miss in international markets and the revised outlook introduced caution among investors.

Argo Graphene Reports Promising Concrete Test Results

Meanwhile, Argo Graphene Solutions announced positive results from a 28-day compressive strength test on its graphene-infused concrete mix in Tennessee. The mix demonstrated an 11% improvement in compressive strength compared to a 4,000 psi design, validating earlier university studies. CEO Scott Smale stated the results aligned with the company’s thesis and signaled potential for long-term market adoption. While the update is encouraging for the firm’s material science division, it does not directly impact ALGO or related crypto markets.

Alvotech Faces Scrutiny Over Manufacturing and Forecasts

In another development, biotech firm Alvotech faced investor backlash following a significant downward revision to its 2025 revenue and adjusted EBITDA guidance. The firm cited a complete response letter from the FDA regarding its key biosimilar candidate, AVT05, highlighting unresolved manufacturing concerns. Shareholder firm Hagens Berman is now investigating potential disclosure issues. The news triggered a 33% drop in Alvotech’s stock but did not directly influence ALGO’s price movement.

Market Implications for ALGO

Despite these developments across e-commerce, construction, and biotechnology sectors, none of the reported events are directly tied to ALGO’s underlying technology or network performance. The token’s continued decline appears to reflect broader market sentiment, including risk-off trading and the absence of a clear short-term catalyst. Analysts project that ALGO’s price will remain range-bound until a meaningful on-chain or ecosystem development emerges. Until then, investors may continue to monitor macroeconomic indicators and sector-specific events for signs of a reversal.

Comments



Add a public comment...
No comments

No comments yet